EA201990744A1 - Стабильная лекарственная форма для парентерального введения тапентадола - Google Patents

Стабильная лекарственная форма для парентерального введения тапентадола

Info

Publication number
EA201990744A1
EA201990744A1 EA201990744A EA201990744A EA201990744A1 EA 201990744 A1 EA201990744 A1 EA 201990744A1 EA 201990744 A EA201990744 A EA 201990744A EA 201990744 A EA201990744 A EA 201990744A EA 201990744 A1 EA201990744 A1 EA 201990744A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tapentadol
composition
present
parenteral administration
medicinal form
Prior art date
Application number
EA201990744A
Other languages
English (en)
Inventor
Ангелика Эллерманн
Ульрих Райнхольд
Ульрике Бертрам
Original Assignee
Грюненталь Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56997349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201990744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Грюненталь Гмбх filed Critical Грюненталь Гмбх
Publication of EA201990744A1 publication Critical patent/EA201990744A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к водной фармацевтической композиции для парентерального введения, содержащей тапентадол или его физиологически приемлемую соль, в которой концентрация тапентадола составляет более 8,00 мг/мл по массе свободного основания тапентадола и относительно общего объема композиции; причем указанная композиция содержит буферную систему; и при этом значение pH композиции составляет от более 3,0 до менее 6,7. Настоящее изобретение также относится к набору, содержащему композицию согласно настоящему изобретению в упаковке. Фармацевтическая композиция согласно настоящему изобретению подходит, в частности для лечения боли, особенно острой боли, предпочтительно у взрослых пациентов.
EA201990744A 2016-09-23 2017-09-22 Стабильная лекарственная форма для парентерального введения тапентадола EA201990744A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16190255 2016-09-23
PCT/EP2017/073983 WO2018055070A1 (en) 2016-09-23 2017-09-22 Stable formulation for parenteral administration of tapentadol

Publications (1)

Publication Number Publication Date
EA201990744A1 true EA201990744A1 (ru) 2019-08-30

Family

ID=56997349

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990744A EA201990744A1 (ru) 2016-09-23 2017-09-22 Стабильная лекарственная форма для парентерального введения тапентадола

Country Status (16)

Country Link
US (1) US10898452B2 (ru)
EP (1) EP3515412A1 (ru)
JP (1) JP7160799B2 (ru)
KR (1) KR20190057349A (ru)
CN (1) CN109996533A (ru)
AU (1) AU2017329964B2 (ru)
BR (1) BR112019005439A2 (ru)
CA (1) CA3037810A1 (ru)
CL (1) CL2019000690A1 (ru)
CO (1) CO2019002557A2 (ru)
EA (1) EA201990744A1 (ru)
EC (1) ECSP19019253A (ru)
IL (1) IL265477A (ru)
MX (1) MX2019003257A (ru)
PE (1) PE20190908A1 (ru)
WO (1) WO2018055070A1 (ru)

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334423D0 (en) 1983-12-23 1984-02-01 Sterwin Ag Composition
GB8334422D0 (en) 1983-12-23 1984-02-01 Sterwin Ag Composition
US4775678A (en) 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
AU614465B2 (en) 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
FR2751875B1 (fr) * 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
US6183758B1 (en) 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6211169B1 (en) 1999-09-29 2001-04-03 Aesgen, Inc. Stable calcitriol solution for packaging into vials
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
JP4905616B2 (ja) 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
FR2832063B1 (fr) 2001-11-15 2004-08-27 Aguettant Lab Procede de production de solutions stables de substances phenoliques et les solutions en resultant
WO2003077897A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040101563A1 (en) 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
CN100344328C (zh) 2002-09-13 2007-10-24 锡德克斯公司 以衍生环糊精稳定化的含有水性填充组合物的胶囊
US6888993B2 (en) 2002-11-27 2005-05-03 Corning Incorporated Dispersion compensating optical fiber for SMF and transmission link including same
ITMI20022748A1 (it) 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
ATE424215T1 (de) 2003-01-08 2009-03-15 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
JP2007538091A (ja) 2004-05-17 2007-12-27 ファーマコフォア・インコーポレイテッド 痛みを処置または予防するための組成物および方法
DE602004007905T2 (de) 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
AU2005259478B2 (en) 2004-07-01 2010-07-15 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP2008539269A (ja) 2005-04-28 2008-11-13 セラクエスト バイオサイエンシズ エルエルシー 疼痛を治療するための方法および組成物
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
WO2007127158A2 (en) 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
CN105561311B (zh) 2006-04-28 2019-07-16 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
DE602007011913D1 (de) 2006-04-28 2011-02-24 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
ES2339403T3 (es) 2006-07-24 2010-05-19 Janssen Pharmaceutica Nv Preparacion de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina.
EP1905440A1 (de) 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
JP2008266168A (ja) 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP1992334A1 (en) 2007-05-08 2008-11-19 Docpharma NV/SA Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation
RS55769B1 (sr) * 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
EP2247283A2 (en) 2007-12-06 2010-11-10 Pain Therapeutics, Inc. Micronized opioid compositions, formulations and dosage forms and methods of making same
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
CA2721014A1 (en) 2008-04-08 2009-10-15 Acino Pharma Ag Aqueous pharmaceutical formulation
PE20190391A1 (es) 2008-10-30 2019-03-13 Gruenenthal Chemie Formas de dosificacion del tapentadol novedosas y potentes
US20110268808A1 (en) 2009-01-09 2011-11-03 Panacea Biotec Ltd. Dual-release pharmaceutical suspension
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
WO2011016487A1 (ja) 2009-08-05 2011-02-10 ナガセ医薬品株式会社 インジゴカルミン製剤
US20120245230A1 (en) 2009-12-10 2012-09-27 Tecnimede-Sociedade Tecnico- Medicinal, S.A. Method and composition for preparing stable liquid formulations of paracetamol
US20110190267A1 (en) 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
NZ602572A (en) 2010-03-30 2014-11-28 Phosphagenics Ltd Transdermal delivery patch
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
PL2680833T3 (pl) * 2011-03-04 2016-08-31 Gruenenthal Gmbh Pozajelitowe podawanie tapentadolu
EA035750B1 (ru) * 2011-03-04 2020-08-05 Грюненталь Гмбх Водная фармацевтическая композиция тапентадола для перорального введения
ES2654407T3 (es) 2011-03-04 2018-02-13 Grünenthal GmbH Composición farmacéutica acuosa semisólida que contiene tapentadol
WO2013144814A1 (en) 2012-03-27 2013-10-03 Fresenius Kabi Oncology Ltd. Stable ready-to-use pharmaceutical composition of pemetrexed
CN103159633B (zh) 2012-07-06 2015-08-12 江苏恩华药业股份有限公司 他喷他多的制备方法及用于制备他喷他多的化合物
WO2014068372A1 (en) * 2012-11-01 2014-05-08 Torrent Pharmaceuticals Ltd Pharmaceutical composition of tapentadol for parenteral administration
EP2968132B1 (en) * 2013-03-14 2017-09-13 Fresenius Kabi Deutschland GmbH Injectable morphine formulations
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
CN103735550B (zh) 2013-12-25 2015-11-18 上海市闸北区中心医院 一种治疗慢性肾脏病心肌损伤的药物组合物及其应用
CN103735500B (zh) 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
PL3273953T3 (pl) * 2015-03-27 2019-07-31 Grünenthal GmbH Stabilny preparat do pozajelitowego podawania tapentadolu
EP3585370A1 (en) * 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic

Also Published As

Publication number Publication date
EP3515412A1 (en) 2019-07-31
CL2019000690A1 (es) 2019-06-14
BR112019005439A2 (pt) 2019-06-18
US10898452B2 (en) 2021-01-26
JP7160799B2 (ja) 2022-10-25
AU2017329964B2 (en) 2022-10-06
IL265477A (en) 2019-05-30
JP2019529442A (ja) 2019-10-17
AU2017329964A1 (en) 2019-03-14
CN109996533A (zh) 2019-07-09
CA3037810A1 (en) 2018-03-29
PE20190908A1 (es) 2019-06-26
WO2018055070A1 (en) 2018-03-29
CO2019002557A2 (es) 2019-05-10
ECSP19019253A (es) 2019-03-29
KR20190057349A (ko) 2019-05-28
US20180085328A1 (en) 2018-03-29
MX2019003257A (es) 2019-06-10

Similar Documents

Publication Publication Date Title
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
EA201790989A1 (ru) Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации
CY1120264T1 (el) Υγρο σκευασμα για εισπνοη που περιεχει rpl554
AR067011A1 (es) Formulaciones de anticuerpos
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
NZ702342A (en) Pharmaceutical formulation
CY1121371T1 (el) Σταθερο σκευασμα για παρεντερικη χορηγηση ταπενταδολης
EA201992685A1 (ru) Раствор леводопы для инфузий
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
EA201990744A1 (ru) Стабильная лекарственная форма для парентерального введения тапентадола
RU2019137020A (ru) Составы со сниженным окислением
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
JP2020040998A5 (ru)
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
TW200626133A (en) Oral medication for twice-daily administration
CY1120282T1 (el) Φαρμακευτικη συνθεση κιτρικης σιλδεναφιλης με την μορφη ενος εναιωρηματος για εκ του στοματος χρηση
AR104051A1 (es) Formulación estable para administración parenteral de tapentadol
EA201690788A1 (ru) Фармацевтические лекарственные формы, содержащие натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат
RU2013127881A (ru) Применение фармацевтической композиции на основе соли четвертичного фосфония и замещенного динитробензофуроксана для лечения пироплазмоза у собак и способ лечения
RU2019140198A (ru) Способ применения элементарной ртути для лечения онкологических заболеваний
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
TH14009A3 (th) สูตรสารละลายในน้ำของริสเพอริโดน
TH14009C3 (th) สูตรสารละลายในน้ำของริสเพอริโดน